Kura Oncology to Report First Quarter 2017 Financial Results
08 mai 2017 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
19 avr. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
07 avr. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
05 avr. 2017 08h00 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017
29 mars 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines, today announced...
Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results
14 mars 2017 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
07 mars 2017 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib
06 mars 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017
27 févr. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product...
Kura Oncology to Participate in Three Upcoming Investor Conferences
09 févr. 2017 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...